Inside the KLOW Stack: The Four Peptides

KLOW blend — the four-arm specification

The KLOW stack is a co-formulated four-peptide research blend. This page specifies each arm as a distinct module. The KLOW peptide blend is not a single compound; it is four compounds co-dissolved at a fixed mass ratio in one lyophilized research vial.

Canonical vial composition (80 mg total):

• GHK-Cu: 50 mg — 62.5% — matrix-and-copper arm
• BPC-157: 10 mg — 12.5% — angiogenic-repair arm
• TB-500: 10 mg — 12.5% — cytoskeletal arm
• KPV: 10 mg — 12.5% — anti-inflammatory arm

No controlled study has tested this combination. The specification below is drawn from the single-component literature.

KPV — anti-inflammatory arm

Molecular specification: L-Lys-L-Pro-L-Val (Lysine-Proline-Valine); MW 342.44 Da; CAS 67727-97-3; C-terminal tripeptide (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH). Vial share: 10 mg / 12.5%.

Mechanism of action: NF-kappaB p65/RelA nuclear-import inhibition in epithelial and immune cells; MAPK (ERK/p38) suppression; reduced TNF-alpha, IL-6, IL-1beta, and IL-8 output. Uptake via PepT1 (SLC15A1, the intestinal di/tripeptide transporter), Km ~160 microM — inflamed mucosa (where PepT1 is upregulated) has a preferential uptake advantage.

Key studies: PepT1-mediated KPV uptake reduced intestinal inflammation in human epithelial cells and murine DSS/TNBS colitis (oral KPV at 100 microM in drinking water) ^[3]. Hyaluronic-acid-functionalized nanoparticle delivery improved mucosal protection and reduced TNF-alpha versus non-targeted routes ^[11]. Self-immolative oral-delivery conjugates addressed the bioavailability challenge for peptides crossing the gut epithelium ^[15].

Human data: KPV human data are restricted to delivery-pilot studies and an IBD-program lineage. No approved monotherapy.

GHK-Cu — mass-dominant matrix-and-copper arm

Molecular specification: Gly-His-Lys chelated 1:1 to Cu(II) (Copper Tripeptide-1, CT-1); MW 402.92 Da; CAS 89030-95-5. Vial share: 50 mg / 62.5% — the dominant component.

Mechanism of action: Procollagen I and IV induction; dermatan sulfate, chondroitin sulfate, and decorin synthesis; broad transcriptomic modulation (~31.2% of human genes at ≥50% change threshold) toward tissue repair, DNA repair, and antioxidant programs ^[5]; copper delivery for lysyl-oxidase-dependent collagen crosslinking; SIRT1 upregulation with STAT3 deacetylation in colitis models.

Key studies: Pickart 2015 review documents topical GHK-Cu outperforming vitamin C and retinoic acid in placebo-controlled collagen production (70% vs 50% vs 40% of treated women) ^[4]. 2018 Connectivity Map analysis: ~31.2% of assayed genes modulated at ≥50% change, with 59% upregulated and 41% suppressed ^[5]. Transdermal copper delivery confirmed: 97 microg/cm^2 dermal depot at 48 h in human ex-vivo skin ^[10]. Liposomal carriers achieve 48.9% elastase inhibition in human epidermal cells with no cytotoxicity ^[13]. Biotinylated GHK scaffold shows antioxidant/antiglycant activity against neurodegeneration-relevant chemistry ^[12].

PK note: Rat plasma data show rapid GHK degradation to dipeptide HK after IV administration ^[8]; no validated human half-life.

Human data: Robust topical/cosmetic evidence; no approved systemic indication.

BPC-157 — angiogenic-repair arm

Molecular specification: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV); MW 1419.53 Da; CAS 137525-51-0. Synthetic 15-AA peptide derived from a partial sequence of a gastric-juice protein (originally developed as PL 14736 for IBD). Vial share: 10 mg / 12.5%.

Mechanism of action: VEGFR2 phosphorylation → PI3K/Akt/eNOS angiogenic cascade; nitric-oxide system modulation partly resistant to L-NAME; growth-hormone-receptor upregulation in tendon fibroblasts.

Key studies: Rat Achilles tendon transection model: BPC-157 at 10 microg, 10 ng, or 10 pg per rat accelerated healing across biomechanical, functional, and histological measures and stimulated tendocyte outgrowth in vitro ^[2]. Fistula resolution via NO-system mediation in rats ^[14]. 2025 IV safety pilot: 10–20 mg in two adults well tolerated, no adverse events, no biomarker changes ^[6]. 2026 Sports Medicine review notes favorable animal outcomes, scarce human safety data ^[7].

Regulatory note: FDA 503A category 2 — may not be used in 503A compounding.

TB-500 — cytoskeletal arm

Molecular specification: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (Ac-LKKTETQ); MW 889.02 Da; synthetic N-acetylated heptapeptide corresponding to the LKKTET actin-binding motif of native thymosin beta-4 (Tbeta4, 43 AA). CAS: none standardized for the fragment. Vial share: 10 mg / 12.5%.

Mechanism of action (fragment): G-actin sequestration via the LKKTET motif — binding monomeric actin, facilitating cell migration. Full-length native Tbeta4 additionally activates integrin-linked kinase and mobilizes epicardial progenitors; these activities are not established for the TB-500 fragment specifically.

Key studies (mostly native Tbeta4): Rat full-thickness wound model: Tbeta4 +42% re-epithelialization at 4d, +61% at 7d, +≥11% wound contraction, increased collagen and angiogenesis; 10 pg sufficient to stimulate keratinocyte migration 2–3-fold ^[1]. LC-MS doping-control identification of TB-500 as Ac-LKKTETQ in equine plasma/urine, LOD 0.01–0.02 ng/mL ^[9]. 2026 Sports Medicine review: animal promise, scarce human safety data ^[7].

WADA status: Thymosin beta-4 is WADA Prohibited List S2 (peptide hormones, growth factors) — banned at all times. TB-500 as the thymosin beta-4 fragment implicates the same prohibition ^[7][9].

KLOW vs glow — the KPV distinction

KLOW and GLOW are related but distinct research blends. GLOW contains GHK-Cu, BPC-157, and TB-500 — three arms. KLOW adds a fourth: KPV, the anti-inflammatory tripeptide from alpha-MSH.

The KPV arm is KLOW's distinguishing feature. It adds the NF-kappaB suppression and PepT1-mediated gut-mucosa uptake mechanism that GLOW lacks. Community accounts frequently attribute the 'broader anti-inflammatory quality' of KLOW relative to GLOW specifically to this arm.

Otherwise: the GHK-Cu, BPC-157, and TB-500 arms are the same as in GLOW; the mass ratio may differ from some GLOW formulations. Neither KLOW nor GLOW is FDA-approved; neither has been tested as a combination in any controlled study. KLOW should not be conflated with WOLVERINE, which is a different blend with a different component set.

KLOW peptide blend — the combination-trial blank

Zero controlled in-vivo or human studies have tested the KLOW four-peptide blend. This is not a gap this site expects to be filled soon — the combination has no regulatory sponsor, no IND, and no published protocol. The entire 'synergy' rationale is a mechanistic extrapolation.

This blank is documented as a structural property of the KLOW research record, not hedged into a footnote. The pharmacokinetic mismatch — fast-clearing KPV and GHK-Cu against sub-30-minute BPC-157 and uncharacterized TB-500 — means even a formal PK study of the co-formulation would be scientifically complex. See the KLOW research page for the full component mechanism record and KLOW references for the citation index.